Navigation Links
Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohn's Disease and Ulcerative Colitis in the United States
Date:6/21/2013

new treatment options is well-recognized," said William J. Sandborn, M.D., chief, division of gastroenterology & professor of medicine, University of California San Diego School of Medicine. "In clinical development, vedolizumab has demonstrated the potential to be another possible treatment option for people with moderately to severely active CD and UC."

The BLA submission was supported by the Phase 3 clinical studies, GEMINI I, GEMINI II, GEMINI III and GEMINI LTS (Long-term Safety), which make up the GEMINI Studies™, a four-study clinical program to investigate the efficacy and safety of vedolizumab on clinical response and remission in moderately to severely active CD and UC patients. Enrolled patients had failed at least one conventional therapy, including corticosteroids, immunomodulators and/or a TNF-alpha antagonist. TNF-alpha antagonist failure patients included those with inadequate response (primary nonresponders), loss of response (secondary nonresponders) or those who were intolerant. Vedolizumab has been studied in 2,700 patients in nearly 40 countries, making it the largest Phase 3 clinical trial program conducted to date simultaneously evaluating both CD and UC.

GEMINI I was designed to assess the efficacy and safety of vedolizumab for inducing and maintaining clinical response and remission in patients with moderately to severely active UC in whom one prior therapy had failed. Key primary endpoints included clinical response at week six and clinical remission at week 52.

GEMINI II was designed to assess the efficacy and safety of vedolizumab for inducing and maintaining clinical response and remission in patients with moderately to severely active CD. Primary outcomes included the number of patients in clinical remission and enhanced clinical response at week six, and clinical remission at 52 weeks.

GEMINI III was designed to assess the efficacy and safety of vedolizumab
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
2. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
3. Takeda to Acquire Inviragen, Inc.
4. Takeda Responds to Verdict in Diabetes Drug Case
5. Takeda Launches New Subsidiary in Ecuador
6. Takeda lanza nueva subsidiaria en Ecuador
7. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
8. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
9. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
10. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
11. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... PITTSBURGH , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage ... at the Australian and New Zealand Forensic Science ... Forensic Sciences in Adelaide, Australia ... discussion concerning the advancements that hyperspectral imaging can ... Jeffrey Beckstead , Director of Product Development ...
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... 2014  Pacific Medical Data Solutions is excited to ... . The main website, along with the site,s blog, ... services and content relevant to the medical billing industry. ... viewers can now better understand how PMDS products help ... create a more visible platform about medical billing best ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4PMDS Announces New Website 2
... AMSTERDAM, April 18, 2012  Leading events organiser UBM Live ... the global UBM Pharma Portfolio, CPhI Southeast Asia (SEA) 2012. ... International Expo in Indonesia, CPhI SEA is the first trade ... the pharmaceutical ingredient sector in the ASEAN region. ...
... -   Retrospective sub-analyses from ADVANCE, ... European Association for the Study of the Liver (EASL) 2012 ... new data for INCIVO (telaprevir) from Phase 3 retrospective sub-analyses ... the Study of the Liver (EASL) in Barcelona.  The data ...
Cached Medicine Technology:Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 2INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 3INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 4INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 5INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 6INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 7
(Date:8/29/2014)... 29, 2014 Thirteen Novant Health ... Great 100 Nurses in North Carolina list ... excellence and provides scholarships to nursing students at all ... Novant Health Presbyterian Medical Center are: Rea ... Nora King, Lissa Ready, Amber Segerlin, Carmen Smith, Melissa ...
(Date:8/29/2014)... By Steven Reinberg ... (HealthDay News) -- The vast majority of American babies ... from serious illnesses, federal health officials said Thursday. ... vaccines that prevent measles, mumps, and rubella (MMR); polio; ... Centers for Disease Control and Prevention. "Nationally, vaccination ...
(Date:8/29/2014)... study from the research group of Dr. John Lewis at ... Research Institute (London, ON) has confirmed that "invadopodia" play a ... in Cell Reports , shows preventing these tentacle-like structures ... , Roughly 2 in 5 Canadians will develop cancer in ... of the disease. In 2014, it,s estimated that nine Canadians ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Floors of ... especially when wearing socks. Also, many patients are relegated ... poor balance, surgery recovery, Alzheimer’s, etc. Two inventors from ... to optimize patient safety. , This special pair of ... It also keeps patients who are relegated to beds ...
(Date:8/29/2014)... University School of Medicine have identified one way the ... insight that could lead to new therapies, in ... Host & Microbe . , In work performed at ... the researchers developed a detailed map of how a ... that takes signaling molecules in and out of the ...
Breaking Medicine News(10 mins):Health News:Great 100 Honors 13 Novant Health Nurses 2Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2
... VILLAGE, Calif., Jan. 21 Specialists On Call,Inc. ... operations and,business development staff to address the accelerating ... largest provider of emergency neurology on-call,services to hospitals, ... to date. , (Logo: ...
... how to avoid most common cause of poisoning in U.S. ... know better, you could confuse carbon monoxide (CO) poisoning with ... has a new fact sheet out to help prevent people ... to the emergency room caused each year by unintentional CO ...
... HAIKOU CITY, China, Jan. 21 /PRNewswire-Asia-FirstCall/ -- ... Board: CPHI), which develops,manufactures, and markets specialty ... preview. , According ... financial year 2008,China Pharma achieved record high ...
... up all over China, more patients will receive dental ... According to Millennium Research Group,s (MRG,s) Chinese ... dental clinics are continuing to emerge in response to ... class and aging population. The establishment of these private ...
... ORLANDO, Fla., Jan. 21 MEDai, Inc., headquartered in ... announced today that has been invited by World Research ... Predictive Modeling for Underwriting Conference. This year,s conference ... on the importance of effectively integrating predictive modeling into ...
... ABT ),today announced financial results for the fourth quarter ended Dec. 31, 2008. ... excluding specified items, were $1.06, ... forecast. Diluted earnings per share under Generally ... were $0.98, up 27.3 percent., -- Worldwide ...
Cached Medicine News:Health News:Specialists On Call Accelerating Access to Emergency Neurology On-Call Services in Texas 2Health News:China Pharma Holdings, Inc., Financial Year 2008 Preview 2Health News:China Pharma Holdings, Inc., Financial Year 2008 Preview 3Health News:Chinese Dental Implant Market Promises Strong Growth 2Health News:MEDai Presents on Transitioning Predictive Modeling Integration From Care Management to Actuarial Applications 2Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 2Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 3Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 4Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 5Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 6Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 7Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 8Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 9Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 10Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 11Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 12Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 13Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 14Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 15Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 16Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 17Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 18Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 19Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 20Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 21Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 22Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 23
... standard trial frames. They are made of optical quality ... box. There are two sets available providing a full ... is that a patient can wear the prism with ... the patient to adapt to the use of the ...
... C Dermatome - reaching a new evolutionary plateau. ... to operate in the pulse mode, or to ... entire instrument and hose assembly is autoclavable and ... 2-, 3-, or 4-inch widths. Simply select the ...
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator (Fenzl), blunt tip angled 45, 12.0 mm from end, fits 0.20 mm diameter holes and larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge ind...
Medicine Products: